Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30608789 | 0.81 | ALDH1A1 (0.69) | CYP1A2MAPK1LMNAALDH1A1MEN1 | |
| SCHEMBL25938257 | 0.74 | ALDH1A1 (0.44) | CYP1A2MAPK1LMNAALDH1A1 | |
| Austricin SCHEMBL14029373 | 0.74 | CYP1A2 (0.97) | CYP1A2MAPK1LMNAALDH1A1MEN1 | |
| Austricin SCHEMBL14190527 | 0.74 | CYP1A2 (0.97) | CYP1A2MAPK1LMNAALDH1A1MEN1 | |
| SCHEMBL3031437 | 0.70 | ALDH1A1 (1.00) | CYP1A2MAPK1LMNAALDH1A1MEN1 | |
| SCHEMBL29973846 | 0.69 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL14215977 | 0.67 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL14533823 | 0.67 | CYP1A2 (0.54) | CYP1A2MAPK1LMNAALDH1A1MEN1 | |
| SCHEMBL1179218 | 0.59 | CYP4Z1 (0.55) | MAPK1LMNAALDH1A1KMT2A | |
| Lactucin SCHEMBL11030649 | 0.57 | CYP19A1 (0.43) | CYP1A2MAPK1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233514-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233514-A1 | ANTIVIRAL COMPOUNDS AND METHODS OF USING THE SAME | ACE2, ACE, EIF2AK2 | CYP1A2 2035/4885MAPK1 4247/4885LMNA 2784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.